看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
/ Q6 ]; M& B; r. Z
2 X( c3 d2 ^5 `, W: M: t& l$ t: P5 n+ X
Currently available feasibility data for possible combination strategies. 1 ]; o, G: |3 y) w8 s. c
————————————————————————————————
# U9 O8 s( {+ I- S$ ACombination Feasibility according to preliminary data ' W" h0 i% r1 B8 v: A6 k
——————————————————————————————————2 z0 {0 {* a$ G! U7 \; e- f
Bevacizumab + sorafenib Yes, reduced dose C5 i- @- B" p9 c4 z: u
Bevacizumab + sunitinib† No
6 ^, }- @' M/ F; MBevacizumab + temsirolimus Yes
# T6 R0 ^( f; S2 I) i2 H% qBevacizumab + everolimus Yes
: H; o0 Z# e: jSorafenib + sunitinib ? , ^/ l6 I, }1 S3 \3 |# q, g7 E+ J4 K
Sorafenib + temsirolimus Yes, reduced dose / l7 C* S ?! D# z- i! C8 v
Sorafenib + everolimus Yes, reduced dose
2 ]0 {, S4 c7 _& l( l/ S/ ySunitinib + temsirolimus† No
6 L! `% x, J4 \2 cSunitinib + everolimus ? ' h5 B; e l( }0 g( i$ ~
Temsirolimus + everolimus ?
6 e" C, ~/ s) k0 Q `————————————————————. \ p, I5 y8 J, G& X1 e
†Led to US FDA warning.0 N( {/ G( K# Z$ D8 m4 m2 T
?: As yet unattempted combination.* o0 q1 S# a9 k6 c0 d4 j' @
|